XLO

Xilio Therapeutics (XLO)

Xilio Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:XLO

1 2 3 4 5 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/07	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:XLO	Xilio Therapeutics Inc
2024/04/02	05 : 05	GlobeNewswire Inc.	Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:XLO	Xilio Therapeutics Inc
2024/03/28	20 : 05	GlobeNewswire Inc.	Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing	NASDAQ:XLO	Xilio Therapeutics Inc
2024/03/28	20 : 00	Business Wire	Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program	NASDAQ:XLO	Xilio Therapeutics Inc
2024/03/28	20 : 00	GlobeNewswire Inc.	Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program	NASDAQ:XLO	Xilio Therapeutics Inc
2024/02/29	06 : 01	GlobeNewswire Inc.	Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference	NASDAQ:XLO	Xilio Therapeutics Inc
2024/02/01	06 : 01	GlobeNewswire Inc.	Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference	NASDAQ:XLO	Xilio Therapeutics Inc
2024/01/20	06 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XLO	Xilio Therapeutics Inc
2024/01/08	21 : 30	GlobeNewswire Inc.	Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies	NASDAQ:XLO	Xilio Therapeutics Inc
2024/01/04	06 : 38	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XLO	Xilio Therapeutics Inc
2024/01/04	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XLO	Xilio Therapeutics Inc
2024/01/04	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XLO	Xilio Therapeutics Inc
2024/01/04	06 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XLO	Xilio Therapeutics Inc
2023/12/07	21 : 45	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XLO	Xilio Therapeutics Inc
2023/12/07	21 : 30	GlobeNewswire Inc.	Xilio Therapeutics Announces Initiation of Enrollment for Phase 1 Combination Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, and Updated Phase 1 Monotherapy Data	NASDAQ:XLO	Xilio Therapeutics Inc
2023/11/10	06 : 17	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:XLO	Xilio Therapeutics Inc
2023/11/10	06 : 13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XLO	Xilio Therapeutics Inc
2023/11/10	06 : 10	Edgar (US Regulatory)	Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]	NASDAQ:XLO	Xilio Therapeutics Inc
2023/11/10	06 : 08	Edgar (US Regulatory)	Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]	NASDAQ:XLO	Xilio Therapeutics Inc
2023/11/10	06 : 05	Edgar (US Regulatory)	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]	NASDAQ:XLO	Xilio Therapeutics Inc
2023/11/10	06 : 01	GlobeNewswire Inc.	Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2023 Financial Results	NASDAQ:XLO	Xilio Therapeutics Inc
2023/11/04	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XLO	Xilio Therapeutics Inc
2023/11/04	01 : 00	GlobeNewswire Inc.	Xilio Announces Initial Monotherapy Safety and Anti-Tumor Activity Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, in Late Line Patients with Advanced Solid Tumors	NASDAQ:XLO	Xilio Therapeutics Inc
2023/10/31	22 : 15	GlobeNewswire Inc.	Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting	NASDAQ:XLO	Xilio Therapeutics Inc
2023/09/28	06 : 02	GlobeNewswire Inc.	Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting	NASDAQ:XLO	Xilio Therapeutics Inc
2023/09/08	05 : 26	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:XLO	Xilio Therapeutics Inc
2023/09/08	05 : 23	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NASDAQ:XLO	Xilio Therapeutics Inc
2023/09/05	21 : 35	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:XLO	Xilio Therapeutics Inc
2023/09/05	21 : 30	GlobeNewswire Inc.	Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer	NASDAQ:XLO	Xilio Therapeutics Inc
2023/09/05	20 : 30	GlobeNewswire Inc.	Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference	NASDAQ:XLO	Xilio Therapeutics Inc